The Dutch part of Eli Lilly's patent and SPC re olanzapine was found to be invalid since the substance olanzapine was already directly and unambiguously disclosed in the earlier Schauzu publication. The error in Schauzu will, according to the court in The Hague, immediately be recognized by the man skilled in the art. The way this error can be corrected can also directly be derived from Schauzu.
There is no trigger for the man skilled in the art to consult an other document.
The court further states that it realizes that its decision deviates from earlier decisions in the United States, China, The Czech Republic, Slovakia, Romania, Ukraine, Russia, Germany, United Kingdom, Austria and Spain. The patent was also invalidated in Canada, but based on a different argument (not a valid selection patent).
Read a summary in English and comments (provided by András Kupecz and Peter Meyer) here.